MNTA
Momenta Pharmaceuticals, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Tue, Nov. 29, 8:18 AM
    • Momenta Pharmaceuticals (NASDAQ:MNTA) is up 10% premarket, albeit on only 1,100 shares, in response to its announcement of positive results from a Phase 3 clinical trial assessing M923, a biosimilar to AbbVie's (NYSE:ABBV) HUMIRA (adalimumab), in patients with moderate-to-severe plaque psoriasis. The study met its primary endpoint of demonstrating equivalence between M923 and HUMIRA as measured by the proportion of patients achieving PASI-75 (75% reduction in psoriasis area and severity).
    • Equivalence was also demonstrated in all secondary endpoints.
    • Complete results will be submitted for presentation at future conferences and for publication.
    | Tue, Nov. 29, 8:18 AM | 13 Comments
  • Tue, Nov. 22, 1:02 PM
    • Aegis Capital initiates coverage of Momenta Pharmaceuticals (MNTA -5.3%) with a Hold rating and $15 (9% upside) price target.
    | Tue, Nov. 22, 1:02 PM | 2 Comments
  • Wed, Nov. 2, 9:52 AM
    • Momenta Pharmaceuticals (MNTA +0.4%) appoints Scott Storer as SVP and Chief Financial Officer effective November 28 succeeding retiring Rick Shea. Mr. Storer joins the firm from Baxalta where he was SVP, Finance.
    | Wed, Nov. 2, 9:52 AM | 1 Comment
  • Wed, Nov. 2, 8:01 AM
    • Momenta Pharmaceuticals (NASDAQ:MNTA): Q3 EPS of -$0.26 beats by $0.04.
    • Revenue of $29.14M (+111.3% Y/Y) beats by $3.46M.
    • Press Release
    | Wed, Nov. 2, 8:01 AM
  • Tue, Nov. 1, 5:30 PM
  • Wed, Oct. 19, 9:25 AM
    • In a regulatory filing, Momenta Pharmaceuticals (NASDAQ:MNTA) reports that EVP, Development and Chief Medical Officer James Roach, M.D., intends to resign effective November 29. No reasons for his decision are provided.
    | Wed, Oct. 19, 9:25 AM | 2 Comments
  • Fri, Oct. 14, 6:49 AM
    • Merck (NYSE:MRK) upgraded to Buy from Neutral by Bank of America. Price target raised to $70 (12% upside) from $57.
    • HCA Holdings (NYSE:HCA) upgraded to Overweight from Sector Weight by KeyBanc.
    • Momenta Pharmaceuticals (NASDAQ:MNTA) upgraded to Overweight from Equal Weight by Barclays. Price target raised to $19 (54% upside) from $13.
    • TESARO (NASDAQ:TSRO) upgraded to Buy from Neutral with a $123 (6% upside) price target by Bank of America.
    • Pfizer (NYSE:PFE) downgraded to Hold from Buy with a $36 (10% upside) price target by Jefferies.
    • Theravance Biopharma (NASDAQ:TBPH) downgraded to Underperform from Neutral by Baird. Price target raised to $24 (25% downside risk) from $19.
    • Ilumina (NASDAQ:ILMN) downgraded to Sell from Neutral by Janney Montgomery Scott. Price target lowered to $125 (9% downside risk) from $155. Downgraded to Neutral from Buy by Citigroup. Price target lowered to $140 (2% upside) from $190.
    • Myriad Genetics (NASDAQ:MYGN) downgraded to Sell from Neutral with a $16 (14% downside risk) price target by Ladenburg Thalmann.
    | Fri, Oct. 14, 6:49 AM | 9 Comments
  • Tue, Oct. 11, 12:45 PM
    | Tue, Oct. 11, 12:45 PM | 1 Comment
  • Tue, Sep. 27, 9:17 AM
    • Shire plc (NASDAQ:SHPG) terminates its collaboration agreement with Momenta Pharmaceuticals (NASDAQ:MNTA) to develop and commercialize M923, a biosimilar to AbbVie's (NYSE:ABBV) HUMIRA (adalimumab). It made the decision after an assessment of its product portfolio following the Baxalta acquisition.
    • Under the terms of the 2011 collaboration agreement between Baxalta and Momenta, the deal will terminate 12 months following the formal notice. Shire will continue to fund the M923 program until then, although preparations to transfer all clinical, regulatory and commercialization activities to Momenta will begin immediately.
    • Momenta better get busy. The FDA just approved Amgen's (NASDAQ:AMGN) version and Samsung Bioepis' version, to be marketed by Biogen (NASDAQ:BIIB), is under regulatory review in Europe. Germany's Merck KGaA (OTCPK:MKGAF)(OTCPK:MKGAY) is also in the mix. Indian outfit Cadila Healthcare launched its HUMIRA biosimilar in India in September 2014.
    | Tue, Sep. 27, 9:17 AM | 7 Comments
  • Fri, Sep. 9, 9:59 AM
    • Eli Lilly (NYSE:LLY) upgraded to Overweight from Neutral by JPMorgan. Price target raised to $95 (20% upside) from $92.
    • Ligand Pharmaceuticals (NASDAQ:LGND) upgraded to Hold from Sell by Deutsche Bank. Price target raised to $110 (2% downside risk) from $105.
    • Gilead Sciences (NASDAQ:GILD) upgraded to Buy from Hold by Jefferies. Price target raised to $91 (16% upside). Morgan Stanley rates it Hold with a price target of $100 (27% upside).
    • Teva Pharmaceutical Industries (NASDAQ:TEVA) upgraded to Outperform from Market Perform with a $66 price target by Oppenheimer.
    • Novo Nordisk (NYSE:NVO) downgraded to Neutral from Overweight by JPMorgan.
    • AbbVie (NYSE:ABBV) downgraded to Neutral from Overweight with a $73 (14% upside) price target by JPMorgan.
    • Cepheid (NASDAQ:CPHD) downgraded to Neutral from Buy by BTIG Research.
    • Tonix Pharmaceuticals (NASDAQ:TNXP) downgraded to Neutral from Buy by Roth Capital.
    • Momenta Pharmaceuticals (NASDAQ:MNTA) downgraded to Sell from Hold with a $6 (48% downside risk) price target by Maxim Group.
    • Biogen (NASDAQ:BIIB) downgraded to Hold from Buy with a $323 (7% upside) price target by Jefferies.
    • Centene (NYSE:CNC) downgraded to Market Perform from Outperform with an $80 (19% upside) price target by Leerink Swann. Wedbush rates it Outperform with an $85 (26% upside) price target.
    | Fri, Sep. 9, 9:59 AM | 12 Comments
  • Fri, Aug. 5, 12:46 PM
    | Fri, Aug. 5, 12:46 PM | 1 Comment
  • Fri, Aug. 5, 11:00 AM
    | Fri, Aug. 5, 11:00 AM | 5 Comments
  • Thu, Aug. 4, 9:15 AM
    • Momenta Pharmaceuticals (NASDAQ:MNTA) -14.8% premarket after saying it has discontinued further accrual of its Phase 2 trial evaluating necuparanib in combination with Abraxane and gemcitabine in patients with advanced metastatic pancreatic cancer.
    • MNTA says data assessed from 120 randomized patients determined that necuparanib in combination with the drugs did not show a sufficient level of efficacy to warrant continued enrollment.
    • MNTA also reported a smaller than expected Q2 loss on 41% lower revenues Y/Y.
    | Thu, Aug. 4, 9:15 AM
  • Thu, Aug. 4, 8:04 AM
    • Momenta Pharmaceuticals (NASDAQ:MNTA): Q2 EPS of -$0.31 beats by $0.03.
    • Revenue of $26.43M (-41.1% Y/Y) beats by $3.53M.
    • Press Release
    | Thu, Aug. 4, 8:04 AM
  • Wed, Aug. 3, 5:30 PM
  • Fri, Jun. 10, 7:19 AM
    • Boston Scientific (NYSE:BSX) initiated with Buy rating and $26 (13% upside) price target by Guggenheim Securities.
    • Zimmer Biomet Holdings (NYSE:ZBH) initiated with Neutral rating and $140 (18% upside) price target by Guggenheim Securities.
    • Edwards Lifesciences (NYSE:EW) initiated with Neutral rating and $120 (18% upside) price target by Guggenheim Securities.
    • Oncobiologics (Pending:ONS) initiated with Buy rating and $15 (218% upside) price target by Cantor Fitzgerald.
    • Walgreens Boots Alliance (NASDAQ:WBA) reinstated with Buy rating and $95 (20% upside) price target by Bank of America.
    • Goldman Sachs initiates coverage of specialty pharma with a Neutral rating: Buy: Jazz Pharma (NASDAQ:JAZZ) - $196 (26% upside) price target, Horizon Pharma (NASDAQ:HZNP) - $24 (30% upside) price target; Neutral: Endo International (NASDAQ:ENDP) - $20 (11% upside) price target, Mallinckrodt (NYSE:MNK) - $73 (17% upside) price target, Momenta Pharmaceuticals (NASDAQ:MNTA) - $14 (19% upside) price target; Concordia Healthcare (NASDAQ:CXRX) - $32 (31% upside) price target; Sell: Impax Laboratories (NASDAQ:IPXL) - $33 (2% downside risk) price target.
    • Biocept (NASDAQ:BIOC) initiated with Buy rating and $1.20 (71% upside) price target by Roth Capital.
    • Seres Therapeutics (NASDAQ:MCRB) initiated with Outperform rating and $40 (22% upside) price target by Cowen & Company.
    • Omeros (NASDAQ:OMER) initiated with Buy rating and $21 (94% upside) price target by Cantor Fitzgerald.
    • Glaukos (NYSE:GKOS) initiated with Buy rating and $35 (30% upside) price target by Cantor Fitzgerald.
    • Shire plc (NASDAQ:SHPG) initiated with Overweight rating and GBX5,600 (34% upside) price target by Morgan Stanley.
    | Fri, Jun. 10, 7:19 AM